Real-World Clinical Experience of Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Olaparib + Abiraterone (PROceed) - Trial NCT06380738
Access comprehensive clinical trial information for NCT06380738 through Pure Global AI's free database. This phase not specified trial is sponsored by AstraZeneca and is currently Recruiting. The study focuses on Metastatic Castration-resistant Prostate Cancer. Target enrollment is 250 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Observational
Sponsor & Location
AstraZeneca
Timeline & Enrollment
N/A
Feb 14, 2024
Jan 31, 2027
Primary Outcome
Time to treatment discontinuation
Summary
PROceed is a multisite, prospective, observational study that describes the real-world use
 and clinical experience of mCRPC patients treated with the combination of olaparib and
 abiraterone in the mCRPC setting. Clinical outcomes will be assessed in patients who are
 either NHA-naive or NHA-exposed prior to initiating olaparib + abiraterone treatment,
 respectively. Patient demographic and clinical characteristics, as well as treatment received
 prior and subsequent to olaparib + abiraterone, will also be described. The study plans to
 enroll patients for a maximum of 2 years and follow up patients from initiation of olaparib
 until 1 year post last patient in.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06380738
Non-Device Trial